Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases.
Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease.
The company is headquartered in New York, New York.